Total pharma industry deals for Q2 2019 worth $121.51bn were announced globally, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the code below into your website to display the chart.

The value marked a decrease of 10.2% over the previous quarter and a rise of 57.7% when compared with the last four-quarter average of $77.6bn.

In terms of number of deals, the sector saw a drop of 11.1% over the last four-quarter average with 368 deals against the average of 414 deals.

In value terms, Europe led the activity with deals worth $89.8bn.

Pharma industry deals in Q2 2019: Top deals

The top five pharma deals accounted for 87.4% of the overall value during Q2 2019.

The combined value of the top five pharma deals stood at $106.21bn, against the overall value of $121.51bn recorded for the quarter. The top announced pharma deal tracked by GlobalData in Q2 2019 was AbbVie’s $85.74bn acquisition of Allergan.

In second place was the $11.4bn acquisition of Array BioPharma by Pfizer and in third place was Novartis‘ $5.3bn asset transaction with Takeda Pharmaceutical.

The $2.2bn acquisition of Peloton Therapeutics by Merck &Inc and Novartis’ acquisition of IFM Tre for $1.58bn held fourth and fifth positions, respectively.

Verdict deals analysis methodology

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.